We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Teva Pharmaceuticals (TEVA) ADR

Sell:$8.58 Buy:$8.59 Change: $0.1 (1.18%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Sell:$8.58
Buy:$8.59
Change: $0.1 (1.18%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Sell:$8.58
Buy:$8.59
Change: $0.1 (1.18%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Contact details

Address:
5 Bazel St, P O B 3190
PETAH TIKVA
49131
Israel
Telephone:
+972 (3) 9267267
Website:
www.tevapharm.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TEVA
ISIN:
US8816242098
Market cap:
$9.76 billion
Shares in issue:
1.10 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kaare Schultz
    President, Chief Executive Officer, Director
  • Eliyahu Kalif
    Chief Financial Officer, Executive Vice President
  • Galia Inbar
    Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer
  • Richard Daniell
    Executive Vice President - European Commercial
  • Sven Dethlefs
    Executive Vice President - North America Commercial
  • Eric Drape
    Executive Vice President - Global Operations
  • Hafrun Fridriksdottir
    Executive Vice President - Global R&D
  • Mark Sabag
    Executive Vice President - International Markets Commercial
  • Eli Shani
    Executive Vice President - Global Marketing and Portfolio
  • David Stark
    Executive Vice President, Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.